Jonathan Izygon

Mr. Jonathan Izygon


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2021 in Neurology International
Verified
Journal Article
Open access
PDF file
ABAmnon Berger
Amnon Berger
ESEmily R. Sottosanti
Emily R. Sottosanti
AWAriel Winnick
Ariel Winnick
JIJonathan Izygon
Jonathan Izygon
KBKevin Berardino
Kevin Berardino
IUIvan Urits
Ivan Urits
Multiple sclerosis (MS) is a prevalent neurologic autoimmune disorder affecting two million people worldwide. Symptoms include gait abnormalities, perception and sensory losses, cranial nerve pathologies, pain, cognitive dysfunction, and emotional aberrancies. Traditional therapy includes corticosteroids for the suppression of relapses and injectable interferons. Recently, several modern therapies—including antibody therapy and oral agents—were approved as disease-modifying agents. Monomethyl fumarate (MMF, Bafiertam) is a recent addition to the arsenal available in the fight against MS and appears to be well-tolerated, safe, and effective. In this paper, we review the evidence available regarding the use of monomethyl fumarate (Bafiertam) in the treatment of relapsing-remitting MS.